NikoleV Posted May 5, 2022 Share Posted May 5, 2022 KRAS: How It Started vs. How It’s Going Posted on April 21, 2022 Dr. Amy Moore and Dr. Upal Basu Roy On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since discovering the KRAS oncogene 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “undruggable.” In the nearly one year since this first FDA approval, advances in the KRAS space have continued to grow rapidly. Here we reflect on the past year and look into our crystal ball to predict where this field is going. Read more of the blog here: https://www.lungevity.org/blogs/kras-how-it-started-vs-how-it’s-going Tom Galli and BridgetO 1 1 Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.